T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34503084/

T-cell specificity can be redirected against tumor antigens either ex vivo using engineered chimeric antigen receptor (CAR) T-cells or in vivo by bridging natural T-cells and tumor cells with bispecific...

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34503088/

1 Department of Clinical Hematology, CHU Montpellier, 34295 Montpellier, France. 2 Institut de Génétique Moléculaire de Montpellier, University Montpellier, CNRS, 34293 Montpellier, France. 3 Department of Biological Hematology, CHU Montpellier,...

Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34505550/

Loncastuximab tesirine is an antiCD19 antibody drug conjugate with a novel cytotoxic payload. Early studies showed this drug is tolerable, with a safety profile that is different from other antibody...

The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34491469/

Lysine-specific demethylase 1 (LSD1, also known as KDM1A) is an attractive agent for treatment of cancer. However, the anti-tumor effect of LSD1 inhibitors against diffuse large B-cell lymphoma (DLBCL) and...

The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34477953/

Patients with high-risk or relapsed aggressive B-cell lymphomas are characterized by poor prognosis. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) can induce durable remissions in these patients and...